Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
Side-by-side · Research reference

EpitalonvsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/37 cited
BHuman-MechanisticDraft11/40 cited
Epitalon
Pineal bioregulator · Telomerase activator
5–10 mgPer cycle doseKhavinson 2003
HumanMechanisticKhavinson 2003
HoursHalf-life (est)
SQ or IM · Abdomen · Daily for 10–20 days
Selank
Anxiolytic + Cognitive · Russian Pharma
150–300 mcg/doseIntranasalZaderej 2014
~30 minOnset
Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter
Epitalon
Selank
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Feedback intact?
No GABA-receptor binding; no dependence reportedMedvedev 2007
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Antibody development

02Dosage Protocols

Parameter
Epitalon
Selank
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
150–300 mcg / dose intranasalZaderej 2014
Frequency
Once daily during a cycle
2–3× per day during stress
Lower / starter dose
2.5 mg / day
75 mcg / dose
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Human-mechanistic + Russian clinical trialsMedvedev 2007
Duration
10–20 day cycles, 1–2× per year
10–14 day cycles, repeated as needed
Reconstitution
Bacteriostatic water
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
Pre-sleep preferred (pineal alignment)
Morning + early afternoon preferred
Half-life
Hours (estimated)
Short (minutes plasma); CNS effect lasts ~3 hr

04Side Effects & Safety

Parameter
Epitalon
Selank
Injection site reaction
Mild irritation
Sleep architecture
Improved subjective sleep quality (anecdotal)
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
Long-term safety
Limited Western RCT data
Limited Western RCT data
Pregnancy / OB
Avoid
Avoid — insufficient data
Antibody formation
Not reported
Nasal irritation
Mild burning or congestion (transient)
Sedation
None — distinct from benzodiazepinesMedvedev 2007
Dependence / withdrawal
None reported in clinical useZaderej 2014
Cognitive impairment
None — opposite effect (enhancement)
Allergic reaction
Rare hypersensitivity
Absolute Contraindications
Epitalon
  • ·Pregnancy / breastfeeding
  • ·Active malignancy or pre-malignant state
Selank
  • ·Pregnancy / breastfeeding
  • ·Hypersensitivity to peptide
Relative Contraindications
Epitalon
  • ·Family history of cancer
Selank
  • ·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter
Epitalon
Selank
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Injection site
SQ — abdomen preferred. Rotate sites.
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
Pre-sleep preferred to align with pineal axis.
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Refrigerate after reconstitution; ≤30 days. Light-protected.
5. Needle
29–31G, 4–8 mm insulin syringe.
Avoid co-administration with strong sedatives or other anxiolytics initially.